Biomarker ID | 790 |
PMID | 22024423 |
Year | 2011 |
Biomarker | cPSA |
Biomarker Basis | Concentration Based(ng/ml) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
Experiment | PCa VS Benign Prostatic Hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 442 patients were chosen such that 131 had prostate cancer and 311 had benign prostatic hyperplasia |
Senstivity | NA |
Specificity | NA |
AUC | Whole dataset: [0.799], tPSA range (0-3.9ng/ml) [0.799]; tPSA range (4-10ng/ml) [0.668]; tPSA range (2-10ng/ml) [0.659]; tPSA range (0-10ng/ml) [0.651]; tPSA range (>10ng/ml) [0.791]; |
Accuracy | NA |
Level Of Significance | p≤ 0.05 |
Method Used | Assays |
Clinical | No |
Remarks | cPSA: Complexed Psa |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | KLK3 |